Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
1053 11 |
Ultima descărcare din IBN: 2023-06-23 12:18 |
Căutarea după subiecte similare conform CZU |
618.33-07-06:618.39-021.3 (1) |
Științe medicale. Medicină (11143) |
SM ISO690:2012 MADAN, Diana, PETROV, Victor, OPALCO, Igor, MANCEVA, Maria, PĂDURE, Valeriu. Semnificaţia markerilor predictivi în diagnosticul naşterilor premature. In: Buletin de Perinatologie, 2015, nr. 1(65), pp. 33-40. ISSN 1810-5289. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Buletin de Perinatologie | ||||||
Numărul 1(65) / 2015 / ISSN 1810-5289 | ||||||
|
||||||
CZU: 618.33-07-06:618.39-021.3 | ||||||
Pag. 33-40 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Introduction: Preterm delivery Intensive research is underway to establish a reliable biomarker (fetal fi bronectin and IGFBP-1 (insulin-like growth factor binding protein-1) that can determine the risk of preterm delivery in pregnant women. Material and methods: 75 pregnant women were examined that were at risk of preterm birth in order to determine the effectiveness of biochemical rapid tests. Results: Analyzing the obtained data, it was found that 60% of patients with symptoms of preterm labor test had a positive result for fetal fi bronectin, a group of asymptomatic patients had negative results in 94.3% of cases. All pregnant women with a diagnosis of preterm labor had done ultrasound study in order to measure the cervical length, showed a statistically signifi cant relationship beginning of preterm birth on the length of the cervix: with CL <25 mm increases the risk of preterm birth. In determining the level of IGFBP-1 protein revealed a direct correlation between the length of the cervix CL <25 mm and the presence of a positive test (IGFBP-1). Conclusion: According to the tests that were done, the use of the negative results of this biochemical marker in establishing the medical decision not to hospitalize the patients with the risk of giving premature birth is coeffi cient preventing the hospitalization and the administration of the necessary tocolytics. To reduce the number of tests used (due to their high cost) it’s preferably their use in pregnant women with a short cervix <25 mm. Continue to be an important problem of perinatal morbidity and mortality. |
||||||
Cuvinte-cheie preterm labor, fetal fi bronectin, IGFBP-1 (insulin-like growth factor binding protein-1 |
||||||
|